Placebo + Naperiglipron for obesity

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 17 Nov 2023: Trial started, NCT06143956
  2. 22 Nov 2023: Trial registered, NCT06143956

The trials

NCT06143956: A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

State
Under way
Phase
Phase 2
People
1,481 planned
Started
17 Nov 2023
Primary completion
Sep 2027
Arms
LY3549492 Obesity ISA GN01, LY3549492 Obesity ISA GN02
Results
None posted
  1. 17 Nov 2023: Trial started
  2. 22 Nov 2023: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.